Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

Science. 1984 Oct 12;226(4671):172-4. Unique Identifier : AIDSLINE MED/85016654
Mitsuya H; Popovic M; Yarchoan R; Matsushita S; Gallo RC; Broder S

Abstract: A recently discovered member of the human T-cell leukemia virus (HTLV) family of retroviruses has been etiologically linked to the acquired immune deficiency syndrome (AIDS). This virus, which has been designated HTLV-III, is tropic for OKT4-bearing (helper-inducer) T cells. Moreover, the virus is cytopathic for these cells. Suramin is a drug used in the therapy of Rhodesian trypanosomiasis and onchocerciasis, and it is known to inhibit the reverse transcriptase of a number of retroviruses. Suramin has now been found to block in vitro the infectivity and cytopathic effect of HTLV-III at doses that are clinically attainable in human beings.
Keywords: Cell Line Cell Survival/DRUG EFFECTS Clone Cells Cytopathogenic Effect, Viral/DRUG EFFECTS Human HTLV-BLV Viruses/*DRUG EFFECTS/PHYSIOLOGY Suramin/*PHARMACOLOGY T-Lymphocytes/*MICROBIOLOGY/PHYSIOLOGY T-Lymphocytes, Helper-Inducer/*MICROBIOLOGY/PHYSIOLOGY Virus Replication/DRUG EFFECTS JOURNAL ARTICLE

KWDcelllinecellsurvival/drugeffectsclonecellscytopathogeniceffect,viral/drugeffectshumanhtlv-blvviruses/KWDdrugeffects/physiologysuramin/KWDpharmacologyt-lymphocytes/KWDmicrobiology/physiologyt-lymphocytes,helper-inducer/KWDmicrobiology/physiologyvirusreplication/drugeffectsjournalarticle
850130
M8510015

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .